The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity
mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-09-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.737083/full |
| _version_ | 1829142594500689920 |
|---|---|
| author | Sonia Tejedor Vaquero Leire de Campos-Mata José María Ramada José María Ramada Pilar Díaz Juan Navarro-Barriuso Clara Ribas-Llaurado Natalia Rodrigo Melero Carlo Carolis Carlo Carolis Andrea Cerutti Andrea Cerutti Andrea Cerutti Ramon Gimeno Ramon Gimeno Ramon Gimeno Giuliana Magri |
| author_facet | Sonia Tejedor Vaquero Leire de Campos-Mata José María Ramada José María Ramada Pilar Díaz Juan Navarro-Barriuso Clara Ribas-Llaurado Natalia Rodrigo Melero Carlo Carolis Carlo Carolis Andrea Cerutti Andrea Cerutti Andrea Cerutti Ramon Gimeno Ramon Gimeno Ramon Gimeno Giuliana Magri |
| author_sort | Sonia Tejedor Vaquero |
| collection | DOAJ |
| description | mRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen. |
| first_indexed | 2024-12-14T20:34:37Z |
| format | Article |
| id | doaj.art-7b252cbe01d34a6ba589bce516c6c7fb |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-14T20:34:37Z |
| publishDate | 2021-09-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7b252cbe01d34a6ba589bce516c6c7fb2022-12-21T22:48:26ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-09-011210.3389/fimmu.2021.737083737083The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing ImmunitySonia Tejedor Vaquero0Leire de Campos-Mata1José María Ramada2José María Ramada3Pilar Díaz4Juan Navarro-Barriuso5Clara Ribas-Llaurado6Natalia Rodrigo Melero7Carlo Carolis8Carlo Carolis9Andrea Cerutti10Andrea Cerutti11Andrea Cerutti12Ramon Gimeno13Ramon Gimeno14Ramon Gimeno15Giuliana Magri16Translational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainEpidemiology and Public Health, Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, SpainCIBER de Epidemiología Y Salud Pública (CIBERESP), Barcelona, SpainCenter for Research in Occupational Health (CISAL), Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, SpainCentre for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, SpainPompeu Fabra University (UPF), Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainDepartment of Medicine, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United StatesCatalan Institute for Research and Advanced Studies (ICREA), Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainDepartment of Pathology, Hospital del Mar, Barcelona, Spain0Department of Cell Biology, Physiology and Immunology, Universitat Autonoma de Barcelona, Barcelona, SpainTranslational Clinical Research Program, Institut Hospital del Mar d’Investigacions Mèdiques (IMIM), Barcelona, SpainmRNA-based vaccines effectively induce protective neutralizing antibodies against SARS-CoV-2, the etiological agent of COVID-19. Yet, the kinetics and compositional patterns of vaccine-induced antibody responses to the original strain and emerging variants of concern remain largely unknown. Here we characterized serum antibody classes and subclasses targeting the spike receptor-binding domain of SARS-CoV-2 wild type and α, β, γ and δ variants in a longitudinal cohort of SARS-CoV-2 naïve and COVID-19 recovered individuals receiving the mRNA-1273 vaccine. We found that mRNA-1273 vaccine recipients developed a SARS-CoV-2-specific antibody response with a subclass profile comparable to that induced by natural infection. Importantly, these antibody responses targeted both wild type SARS-CoV-2 as well as its α, β, γ and δ variants. Following primary vaccination, individuals with pre-existing immunity showed higher induction of all antibodies but IgG3 compared to SARS-CoV-2-naïve subjects. Unlike naïve individuals, COVID-19 recovered subjects did not mount a recall antibody response upon the second vaccine dose. In these individuals, secondary immunization resulted in a slight reduction of IgG1 against the receptor-binding domain of β and γ variants. Despite the lack of recall humoral response, vaccinees with pre-existing immunity still showed higher titers of IgG1 and IgA to all variants analyzed compared to fully vaccinated naïve individuals. Our findings indicate that mRNA-1273 vaccine triggered cross-variant antibody responses with distinct profiles in vaccinees with or without pre-existing immunity and suggest that individuals with prior history of SARS-CoV-2 infection may not benefit from the second mRNA vaccine dose with the current standard regimen.https://www.frontiersin.org/articles/10.3389/fimmu.2021.737083/fullhumoral immunityantibody subclassesCOVID-19variants of concernmRNA vaccination |
| spellingShingle | Sonia Tejedor Vaquero Leire de Campos-Mata José María Ramada José María Ramada Pilar Díaz Juan Navarro-Barriuso Clara Ribas-Llaurado Natalia Rodrigo Melero Carlo Carolis Carlo Carolis Andrea Cerutti Andrea Cerutti Andrea Cerutti Ramon Gimeno Ramon Gimeno Ramon Gimeno Giuliana Magri The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity Frontiers in Immunology humoral immunity antibody subclasses COVID-19 variants of concern mRNA vaccination |
| title | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
| title_full | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
| title_fullStr | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
| title_full_unstemmed | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
| title_short | The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity |
| title_sort | mrna 1273 vaccine induces cross variant antibody responses to sars cov 2 with distinct profiles in individuals with or without pre existing immunity |
| topic | humoral immunity antibody subclasses COVID-19 variants of concern mRNA vaccination |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.737083/full |
| work_keys_str_mv | AT soniatejedorvaquero themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT leiredecamposmata themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT josemariaramada themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT josemariaramada themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT pilardiaz themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT juannavarrobarriuso themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT clararibasllaurado themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT nataliarodrigomelero themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT carlocarolis themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT carlocarolis themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT giulianamagri themrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT soniatejedorvaquero mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT leiredecamposmata mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT josemariaramada mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT josemariaramada mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT pilardiaz mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT juannavarrobarriuso mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT clararibasllaurado mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT nataliarodrigomelero mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT carlocarolis mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT carlocarolis mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT andreacerutti mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT ramongimeno mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity AT giulianamagri mrna1273vaccineinducescrossvariantantibodyresponsestosarscov2withdistinctprofilesinindividualswithorwithoutpreexistingimmunity |